Many TAA and tumor-specific antigens have been used as target structures for the development of colorectal cancer therapies or vaccines such as melanoma associated antigen (MAGE), vascular endothelial growth factor receptor 1 and 2 (VEGFR-1 and VEGFR-2), EpCAM and EGFR. Here, FLT1 is linked to neoplasm.